Strategic Portfolio Addition Elevates Technical Leadership in Specialty Lubrication This is a defining moment for Kano.
Spun out of MIT, the company is engineering a new class of biomolecules at 10x lower cost and drastically increased scale to advance gene editing toward cures for complex diseases. “We believe curing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results